Design and methodology of the CAPRICORN trial - a randomised double blind placebo controlled study of the impact of carvedilol on morbidity and mortality in patients with left ventricular dysfunction after myocardial infarction.
Dargie
H J
HJ
Clinical Research Initiative in Heart Failure, University of Glasgow, West Medical Building, G 12 8 QQ, Glasgow, UK.h.dargie@bio.gla.ac.uk
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D002227:Carbazoles / Q000627:therapeutic use*; D000077261:Carvedilol; D004311:Double-Blind Method; D006801:Humans; D015994:Incidence; D009203:Myocardial Infarction / Q000150:complications / Q000401:mortality*; D017410:Practice Guidelines as Topic; D011412:Propanolamines / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic / Q000379:methods*; D012107:Research Design; D012449:Safety; D015996:Survival Rate; D006113:United Kingdom / Q000453:epidemiology; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy / Q000209:etiology / Q000401:mortality*
D000319:Adrenergic beta-Antagonists; D002227:Carbazoles; D011412:Propanolamines; D000077261:Carvedilol